Lupin Receives U.S. FDA Approval for Amifampridine Tablets
· prnewswire.com · popularity 16/100 · 0 similar stories today · Pharmaceuticals & Medical Research (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
As the First-To-File, Lupin is Eligible for 180-Day Shared Generic Exclusivity MUMBAI, India and NAPLES, Fla., Nov. 2, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 16.